Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 2Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 29Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Head & Neck 1CNS 1

Conditions

Head and Neck Neoplasms 1

Interventions

Cisplatin 144Radiotherapy 71Fluorouracil 50Radiotherapy, Intensity-Modulated 45Docetaxel 39Gemcitabine 38Cetuximab 38Carboplatin 31pembrolizumab 25Capecitabine 22Drug Therapy 17toripalimab 14Paclitaxel 14camrelizumab 10Surgical Procedures, Operative 10Nivolumab 10Chemoradiotherapy 10nimotuzumab 9Radiation 9Neoadjuvant Therapy 8Methotrexate 8Magnetic Resonance Spectroscopy 8Chemotherapy, Adjuvant 8nedaplatin 7Thyrotropin Alfa 7Platinum 7tislelizumab 6spartalizumab 6Standard of Care 6Specimen Handling 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lapatinib × Head & Neck × Clear all
NCT00424255 2014-07-18

Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery

GlaxoSmithKline

Phase 3 Completed
688 enrolled 19 charts
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡